ICICI Securities Ltd. | Retail Equity Research The Q4 numbers released by Glenmark Pharma and Dr Reddy's have once again showcased continuing (and perhaps worsening) pricing pressure in the US base business. Both the managements indicated high single digit to low double digit price erosion in the US in the backdrop of client consolidation and intense competition, mainly in the oral segment. In a major development, the government has, on record, made its intention to mandate doctors to write generic names of medicines on the...